Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with

Aged Cohort Studies Dipeptides Heterocyclic Compounds, 1-Ring Humans Male Middle Aged Prostate-Specific Antigen Prostatic Neoplasms, Castration-Resistant
177Lu RESIST-PC metastatic castration-resistant prostate cancer molecular radiotherapy prospective randomized phase 2 trial prostate-specific membrane antigen radionuclide therapy theranostics

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
10 2021
Historique:
received: 20 01 2021
accepted: 13 05 2021
pubmed: 22 5 2021
medline: 6 1 2022
entrez: 21 5 2021
Statut: ppublish

Résumé

The objective of this study was to determine prospectively the efficacy profile of 2 activity regimens of

Identifiants

DOI: 10.2967/jnumed.121.261982 PMID: 34016732 PMC: PMC8724893
pubmed: 34016732
pii: jnumed.121.261982
doi: 10.2967/jnumed.121.261982
pmc: PMC8724893
doi:

Substances chimiques

Dipeptides 0
Heterocyclic Compounds, 1-Ring 0
PSMA-617 0
Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1440-1446

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA092131
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Références

J Nucl Med. 2020 Jun;61(6):857-865
pubmed: 31732676
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):496-508
pubmed: 29247284
AJR Am J Roentgenol. 2019 Aug;213(2):275-285
pubmed: 30995089
J Soc Integr Oncol. 2006 Fall;4(4):194-8
pubmed: 17022927
Lancet. 2021 Feb 27;397(10276):797-804
pubmed: 33581798
J Clin Oncol. 2010 Mar 20;28(9):1496-501
pubmed: 20159814
Eur J Nucl Med Mol Imaging. 2020 Aug;47(9):2106-2112
pubmed: 32062682
J Support Oncol. 2011 Mar-Apr;9(2):72-8
pubmed: 21542414
J Nucl Med. 2017 Jan;58(1):85-90
pubmed: 27765862
Eur Urol. 2019 Jun;75(6):920-926
pubmed: 30473431
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
Ann Acad Med Singap. 1994 Mar;23(2):129-38
pubmed: 8080219
BMC Med Res Methodol. 2020 Jan 16;20(1):10
pubmed: 31948397

Auteurs

Jeremie Calais (J)

Andrei Gafita (A)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.

Matthias Eiber (M)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Department of Nuclear Medicine, Technical University Munich, Klinikum rechts der Isar, Munich, Germany.

Wesley R Armstrong (WR)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.

Jeannine Gartmann (J)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.

Pan Thin (P)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.

Kathleen Nguyen (K)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.

Vincent Lok (V)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.

Laura Gosa (L)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.

Tristan Grogan (T)

Department of Medicine Statistics Core, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

Rouzbeh Esfandiari (R)

Excel Diagnostics and Nuclear Oncology Center, Houston, Texas.

Martin Allen-Auerbach (M)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, California.
Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.

Andrew Quon (A)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, California.
Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.

Shadfar Bahri (S)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, California.
Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.

Pawan Gupta (P)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.

Linda Gardner (L)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.

David Ranganathan (D)

RadioMedix, Inc., Houston, Texas; and.

Roger Slavik (R)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.

Magnus Dahlbom (M)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Physics & Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

Ken Herrmann (K)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.

Ebrahim Delpassand (E)

Excel Diagnostics and Nuclear Oncology Center, Houston, Texas.
RadioMedix, Inc., Houston, Texas; and.

Wolfgang P Fendler (WP)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.

Johannes Czernin (J)

Ahmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California Los Angeles, Los Angeles, California.
Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, California.
Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Prospective phase 2 trial of PSMA-targeted...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Prospective phase 2 trial of PSMA-targeted...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Oligopeptides › Dipeptides › Prospective phase 2 trial of PSMA-targeted...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Prospective phase 2 trial of PSMA-targeted...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Prospective phase 2 trial of PSMA-targeted...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Prospective phase 2 trial of PSMA-targeted...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Antigène spécifique de la prostate › Prospective phase 2 trial of PSMA-targeted...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Tumeurs prostatiques résistantes à la castration › Prospective phase 2 trial of PSMA-targeted...